We are experiencing some temporary issues. The market data on this page is currently delayed. Please bear with us as we address this and restore your personalized lists.
S&P Futures
5,476.00 -0.75 (-0.01%) Dow Futures
39,124.00 -23.00 (-0.06%) Nasdaq Futures
19,777.25 +14.00 (+0.07%) Russell 2000 Futures
2,017.40 +0.50 (+0.02%) Crude Oil
82.34 +0.17 (+0.21%) Gold
2,373.90 +4.90 (+0.21%)
Upgrade to begin using premium screener tools and get so much more.
Yahoo FinanceParamount is an impaired asset with a broken deal process, according to top adviser to Disney CEO
Paramount's troubles have media veterans whispering about what could be next.
Investor's Business DailySarepta Skyrockets After Nabbing A Broad Label For Its Duchenne Gene Therapy
Sarepta rocketed late Thursday after the FDA approved its Duchenne muscular dystrophy gene therapy for all patients age 4 and older.
The Wall Street JournalWhy Wall Street Is Chasing Ozempic Wannabes
Big Pharma can’t seem to get investors hyped on much beyond obesity, so many are jumping in. Most won’t win.
Investor's Business DailyPfizer Lingers Near 11-Year Low Despite Promising Cancer Drug Updates — Is It A Sell?
Pfizer stock is struggling to retake its 200-day line despite promising updates in cancer treatment. Is PFE stock now a sell?
BioPharma DiveSarepta Duchenne gene therapy wins broader use from FDA
The decision makes Elevidys available to Duchenne patients at least 4 years of age, despite mixed trial results that have led to skepticism about its effectiveness.
LA TimesMoviePass secures investment from Comcast-backed venture firm amid comeback attempt
MoviePass, the famously cheap cinema subscription service that crashed and burned, has a new investor: Comcast's Forecast Labs.
Medical Device NetworkRoche launches B-cell lymphoma diagnostic assay in Europe
Roche’s Ventana B-cell lymphoma diagnostic assay can detect and differentiate B-cell lymphomas and plasma cell neoplasms from a normal immune response.
South China Morning PostHuawei's HarmonyOS gears up for faster expansion on back of major apps WeChat and Douyin
Huawei Technologies is looking to further expand the presence of its HarmonyOS mobile platform on the back of two of mainland China's biggest social media apps, WeChat from Tencent Holdings and ByteDance-owned Douyin. Shenzhen-based Huawei is close to reaching a deal with Tencent to make its super app WeChat fully operational on HarmonyOS without sharing any revenue, according to a report by Bloomberg on Wednesday, citing anonymous sources. While Douyin now has a HarmonyOS-compatible version ava
- South China Morning Post
Tencent pulls hit game DnF Mobile from app stores of Huawei, Oppo and Vivo in sign of dispute
DnF Mobile will no longer be available on some Android platforms from Thursday, according to a notice released on Wednesday by the game's operating team. The affected app stores - including those of Huawei, Oppo and Vivo - were identified on the same day in a report by Chinese media outlet 21st Century Business Herald, which cited anonymous sources. The DnF Mobile team recommended that new users on Android systems download the game from its official website amid "adjustments in our cooperation with certain app stores".
ReutersTencent's 'Dungeon & Fighter' game pulled from some Android app stores
Tencent is removing from Thursday its hit mobile game "Dungeon & Fighter" (DnF Mobile) from selected Android app stores as its contracts have expired, the company said. Game developers in China have long had a contentious relationship with distributors over issues such as revenue sharing, as mobile games become increasingly popular in the broader game market. In the case of partnerships between developers and Android app stores, the standard 50% revenue share split has often been a bone of contention.
